Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Largest Insider Buys in Sector
BHVN Stock Price History Chart
BHVN Stock Performance
About Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Insider Activity of Biohaven Pharmaceutical Holding Company Ltd.
Over the last 12 months, insiders at Biohaven Pharmaceutical Holding Company Ltd. have bought $23.79M and sold $0 worth of Biohaven Pharmaceutical Holding Company Ltd. stock.
On average, over the past 5 years, insiders at Biohaven Pharmaceutical Holding Company Ltd. have bought $23.97M and sold $23.96M worth of stock each year.
Highest buying activity among insiders over the last 12 months: CHILDS JOHN W (director) — $13.05M. Coric Vlad (Chief Executive Officer) — $6M. Bailey Gregory (director) — $3.73M.
The last purchase of 29,000 shares for transaction amount of $1.04M was made by CHILDS JOHN W (director) on 2024‑12‑30.
List of Insider Buy and Sell Transactions, Biohaven Pharmaceutical Holding Company Ltd.
| 2024-12-30 | director | 29,000 0.0281% | $35.94 | $1.04M | +7.99% | |||
| 2024-10-02 | Chief Executive Officer | 21,052 0.0215% | $47.50 | $999,970 | -2.42% | |||
| 2024-10-02 | director | 21,052 0.0215% | $47.50 | $999,970 | -2.42% | |||
| 2024-09-24 | director | 5,000 0.0047% | $44.19 | $220,966 | +6.55% | |||
| 2024-07-18 | director | 28,400 0.0218% | $35.67 | $1.01M | +19.98% | |||
| 2024-06-17 | Chief Scientific Officer | 30,000 0.0217% | $33.58 | $1.01M | +21.73% | |||
| 2024-05-30 | director | 28,000 0.0214% | $35.58 | $996,240 | +11.84% | |||
| 2024-05-13 | director | 28,500 0.0215% | $35.17 | $1M | +15.81% | |||
| 2024-05-13 | director | 15,000 0.011% | $34.19 | $512,877 | +15.81% | |||
| 2024-04-24 | director | 25,503 0.0215% | $39.18 | $999,169 | +1.47% | |||
| 2024-04-22 | director | 195,121 0.1719% | $41.00 | $8M | +2.50% | |||
| 2024-04-22 | Chief Executive Officer | 121,951 0.1075% | $41.00 | $5M | +2.50% | |||
| 2024-04-22 | director | 48,780 0.043% | $41.00 | $2M | +2.50% | |||
| 2023-12-29 | Sale | director | 11,000 0.0099% | $41.79 | $459,663 | +1.05% | ||
| 2023-10-05 | director | 454,545 0.2149% | $22.00 | $10M | +61.12% | |||
| 2023-10-05 | Chief Executive Officer | 454,545 0.2149% | $22.00 | $10M | +61.12% | |||
| 2023-10-05 | Chief Financial Officer | 22,727 0.0107% | $22.00 | $499,994 | +61.12% | |||
| 2023-10-04 | director | 17,817 0.0086% | $22.57 | $402,094 | +69.45% | |||
| 2023-08-30 | director | 50,000 0.0198% | $18.44 | $922,180 | +106.32% | |||
| 2023-08-04 | director | 100,000 0.0425% | $19.78 | $1.98M | +84.03% |
Insider Historical Profitability
| CHILDS JOHN W | director | 2368741 2.3425% | $36.86 | 20 | 2 | +60.31% |
| Bailey Gregory | director | 1620071 1.6021% | $36.86 | 9 | 22 | +43.47% |
| Coric Vlad | Chief Executive Officer | 861942 0.8524% | $36.86 | 8 | 8 | +25.36% |
| Car Bruce | Chief Scientific Officer | 30000 0.0297% | $36.86 | 1 | 0 | |
| Cha Albert | director | 1976818 1.9549% | $36.86 | 1 | 0 | |
| Doogan Declan | director | 870648 0.861% | $36.86 | 0 | 31 | |
| Buten Matthew | Chief Financial Officer | 189380 0.1873% | $36.86 | 2 | 0 | +39.3% |
| PORTAGE BIOTECH INC. | 54494 0.0539% | $36.86 | 0 | 7 | ||
| GREGORY JULIA P | director | 25665 0.0254% | $36.86 | 1 | 3 | +17.49% |
| Engelhart James | Chief Financial Officer | 11196 0.0111% | $36.86 | 2 | 9 | |
| Stock Elyse | Chief Medical Officer | 7467 0.0074% | $36.86 | 0 | 5 | |
| Conway Charles | Chief Scientific Officer | 4000 0.004% | $36.86 | 1 | 0 | |
| Clark George C. | VP, Chief Accounting Officer | 4065 0.004% | $36.86 | 0 | 3 | |
| Gentile Kimberly | SVP, Clinical Operations | 3639 0.0036% | $36.86 | 0 | 11 | |
| Antonijevic Irina | director | 2535 0.0025% | $36.86 | 0 | 1 | |
| JONES WILLIAM A JR | CCO-Migraine & Common Disease | 1755 0.0017% | $36.86 | 0 | 1 | |
| AGUIAR ERIC | director | 1250 0.0012% | $36.86 | 0 | 7 | |
| Tilton John | Chief Commercial Officer | 770 0.0008% | $36.86 | 0 | 4 | |
| Berman Robert | Special Projects & Med Ovrsght | 341 0.0003% | $36.86 | 2 | 22 |